Shares of Click Holdings Limited (NASDAQ:CLIK – Get Free Report) were up 1.4% during mid-day trading on Friday . The company traded as high as $1.52 and last traded at $1.44. 104,765 shares were traded during mid-day trading, a decline of 46% from the average session volume of 192,340 shares. The stock had previously closed at $1.42.
Analyst Ratings Changes
CLIK has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Click in a report on Wednesday, June 24th. Wall Street Zen raised Click to a “hold” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Get Our Latest Research Report on Click
Click Price Performance
Click (NASDAQ:CLIK – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.10 EPS for the quarter. The company had revenue of $3.79 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Click stock. Renaissance Technologies LLC acquired a new position in Click Holdings Limited (NASDAQ:CLIK – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click as of its most recent filing with the Securities and Exchange Commission.
Click Company Profile
Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.
Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.
Further Reading
- Five stocks we like better than Click
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Click Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Click and related companies with MarketBeat.com's FREE daily email newsletter.
